Science & Technology Partners L.P. Purchases Shares of 51,750 Glaukos Co. (NYSE:GKOS)

Science & Technology Partners L.P. acquired a new stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 51,750 shares of the medical instruments supplier's stock, valued at approximately $7,759,000. Glaukos makes up about 2.4% of Science & Technology Partners L.P.'s holdings, making the stock its 16th largest position. Science & Technology Partners L.P. owned 0.09% of Glaukos at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GKOS. Vanguard Group Inc. grew its stake in shares of Glaukos by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 5,974,971 shares of the medical instruments supplier's stock worth $895,887,000 after buying an additional 101,838 shares in the last quarter. Invesco Ltd. increased its stake in Glaukos by 4.9% during the fourth quarter. Invesco Ltd. now owns 1,458,635 shares of the medical instruments supplier's stock worth $218,708,000 after acquiring an additional 68,310 shares during the last quarter. Geode Capital Management LLC raised its position in Glaukos by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 1,197,215 shares of the medical instruments supplier's stock valued at $179,555,000 after purchasing an additional 25,199 shares during the period. Alliancebernstein L.P. lifted its stake in shares of Glaukos by 1,235.4% in the 4th quarter. Alliancebernstein L.P. now owns 816,153 shares of the medical instruments supplier's stock valued at $122,374,000 after purchasing an additional 755,035 shares during the last quarter. Finally, William Blair Investment Management LLC purchased a new position in shares of Glaukos in the 4th quarter worth approximately $121,390,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Stock Up 1.2 %

Shares of NYSE:GKOS traded up $1.19 during trading hours on Friday, hitting $96.62. The company's stock had a trading volume of 545,203 shares, compared to its average volume of 646,054. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The firm's fifty day moving average price is $102.37 and its 200 day moving average price is $130.13. Glaukos Co. has a 52 week low of $77.91 and a 52 week high of $163.71. The company has a market capitalization of $5.52 billion, a price-to-earnings ratio of -33.67 and a beta of 0.88.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company had revenue of $105.50 million during the quarter, compared to analysts' expectations of $100.72 million. As a group, research analysts expect that Glaukos Co. will post -1.08 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the transaction, the chief financial officer now directly owns 53,431 shares in the company, valued at $5,708,568.04. The trade was a 2.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Tomas Navratil sold 3,416 shares of the company's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on GKOS shares. Stifel Nicolaus raised their price target on Glaukos from $153.00 to $175.00 and gave the stock a "buy" rating in a research report on Tuesday, December 31st. Wells Fargo & Company raised their target price on shares of Glaukos from $153.00 to $160.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Needham & Company LLC upped their price target on shares of Glaukos from $149.00 to $176.00 and gave the company a "buy" rating in a report on Friday, February 21st. Piper Sandler decreased their price objective on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating for the company in a research note on Tuesday, April 15th. Finally, Truist Financial reduced their price target on Glaukos from $185.00 to $140.00 and set a "buy" rating on the stock in a report on Friday, April 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $156.17.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.